Mahjabeen Yaseen1, Furqan Ahmad Jarullah2, Sadia Yaqoob2, Hassan Abdullah Shakeel3, Hamza Maqsood4, Sadiq Naveed5. 1. Fazaia Ruth Pfau Medical College, Karachi, Pakistan. 2. Jinnah Medical and Dental College, Karachi, Pakistan. 3. Nishtar Medical Univeristy, Multan, Pakistan. 4. Nishtar Medical Univeristy, Multan, Pakistan. hamzamaqsood381@gmail.com. 5. Institute of Living, Hartford, CT, USA.
Abstract
OBJECTIVES: Restless Legs Syndrome (RLS) is commonly known to cause morbidity in patients on hemodialysis, making them prone to chronic mental health illnesses such as depression and anxiety, and also adversely impact quality of life. In this study, we examined the association of quality of life, anxiety, and depression with restless leg syndrome in the hemodialysis patients at Karachi Institute of Kidney Diseases. RESULTS: About 26.7% of the participants reported RLS among the sample size Presence of RLS was not associated with quality of life, depression, and anxiety. However, p-values < 0.05 were significant for body-mass index (BMI), diabetes mellitus as a cause of end-stage renal disease, and serum albumin levels. Majority (82.5%) of the RLS-diagnosed patients had moderate to severe symptoms with 16 (40%) and 17 (42.5%) clients, respectively.
OBJECTIVES:Restless Legs Syndrome (RLS) is commonly known to cause morbidity in patients on hemodialysis, making them prone to chronic mental health illnesses such as depression and anxiety, and also adversely impact quality of life. In this study, we examined the association of quality of life, anxiety, and depression with restless leg syndrome in the hemodialysis patients at Karachi Institute of Kidney Diseases. RESULTS: About 26.7% of the participants reported RLS among the sample size Presence of RLS was not associated with quality of life, depression, and anxiety. However, p-values < 0.05 were significant for body-mass index (BMI), diabetes mellitus as a cause of end-stage renal disease, and serum albumin levels. Majority (82.5%) of the RLS-diagnosed patients had moderate to severe symptoms with 16 (40%) and 17 (42.5%) clients, respectively.
Authors: J Winkelmann; M Prager; R Lieb; H Pfister; B Spiegel; H-U Wittchen; F Holsboer; C Trenkwalder; A Ströhle Journal: J Neurol Date: 2005-01 Impact factor: 4.849
Authors: Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi Journal: Sleep Med Date: 2003-03 Impact factor: 3.492
Authors: Arthur S Walters; Cheryl LeBrocq; Anjana Dhar; Wayne Hening; Ray Rosen; Richard P Allen; Claudia Trenkwalder Journal: Sleep Med Date: 2003-03 Impact factor: 3.492
Authors: Hochang B Lee; Wayne A Hening; Richard P Allen; Amanda E Kalaydjian; Christopher J Earley; William W Eaton; Constantine G Lyketsos Journal: J Neuropsychiatry Clin Neurosci Date: 2008 Impact factor: 2.198